Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus |
| |
| Authors: | Capucine Daridon Daniela Blassfeld Karin Reiter Henrik E Mei Claudia Giesecke David M Goldenberg Arne Hansen Arwed Hostmann Daniela Frölich Thomas Dörner |
| |
| Affiliation: | 1.Charite - Universitätsmedizin Berlin, CC12 Dept. Medicine/Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin 10117, Germany;2.Deutsches Rheumaforschungszentrum (DRFZ), Chariteplatz 1, Berlin 10117, Germany;3.Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Ave., Belleville, NJ 07109, USA |
| |
| Abstract: | Introduction Epratuzumab, a humanized anti-CD22 monoclonal antibody, is under investigation as a therapeutic antibody in non-Hodgkin's lymphoma and systemic lupus erythematosus (SLE), but its mechanism of action on B-cells remains elusive. Treatment of SLE patients with epratuzumab leads to a reduction of circulating CD27negative B-cells, although epratuzumab is weakly cytotoxic to B-cells in vitro. Therefore, potential effects of epratuzumab on adhesion molecule expression and the migration of B-cells have been evaluated. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
